Advances in the assessment of minimal residual disease in mantle cell lymphoma.
Dayoung JungPreetesh JainYixin YaoMichael L WangPublished in: Journal of hematology & oncology (2020)
The clinical impact of minimal residual disease detection at early time points or during follow-ups has been shown to accurately predict relapses among patients with lymphomas, mainly in follicular and diffuse large B cell lymphoma. The field of minimal residual disease testing in mantle cell lymphoma is still evolving but has great impact in determining the prognosis. Flow cytometry and polymerase chain reaction-based testing are most commonly used methods in practice; however, these methods are not sensitive enough to detect the dynamic changes that underline lymphoma progression. Newer methods using next-generation sequencing, such as ClonoSeq, are being incorporated in clinical trials. Other techniques under evolution include CAPP-seq and anchored multiplex polymerase chain reaction-based methods. This review article aims to provide a comprehensive update on the status of minimal residual disease detection and its prognostic effect in mantle cell patients. The role of circulating tumor DNA-based minimal residual disease detection in lymphomas is also discussed.
Keyphrases
- circulating tumor
- diffuse large b cell lymphoma
- real time pcr
- flow cytometry
- clinical trial
- loop mediated isothermal amplification
- cell free
- label free
- epstein barr virus
- single cell
- circulating tumor cells
- ejection fraction
- primary care
- newly diagnosed
- end stage renal disease
- prognostic factors
- randomized controlled trial
- stem cells
- high throughput
- gene expression
- copy number
- cell therapy
- patient reported outcomes
- patient reported
- study protocol
- open label
- quantum dots